At pitney bowes, value-based insurance design cut copayments and increased drug adherence

Health Affairs

Volumn 29, Issue 11, 2010, Pages 1995-2001

  Choudhry, Niteesh K ^a   Fischer, Michael A ^a   Avorn, Jerry ^a   Schneeweiss, Sebastian ^a   Solomon, Daniel H ^a   Berman, Christine ^b   Jan, Saira ^c   Liu, Jun ^d   Lii, Joyce ^d   Alan Brookhart, M ^e   Mahoney, John J ^b   Shrank, William H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Pitney Bowes Inc   (United States)

^c HORIZON BLUE CROSS BLUE SHIELD OF NEW JERSEY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COHORT ANALYSIS; COST CONTROL; ECONOMICS; FEMALE; HEALTH CARE QUALITY; HEALTH INSURANCE; HEALTH SERVICES RESEARCH; HUMAN; MALE; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATIENT COMPLIANCE; UNITED STATES;

COHORT STUDIES; COST SAVINGS; FEMALE; HEALTH BENEFIT PLANS, EMPLOYEE; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MIDDLE AGED; ORGANIZATIONAL CASE STUDIES; PATIENT COMPLIANCE; QUALITY ASSURANCE, HEALTH CARE; UNITED STATES;

EID: 79952278274     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2010.0336     Document Type: Article

References (25)

1. Rosenthal MB, Landon BE, Normand SL, Frank RG, Ahmad TS, Epstein AM. Employers' use of valuebased purchasing strategies. JAMA. 2007;298(19):2281-8.
2. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1): 61-9.
3. Schneeweiss S, Patrick AR, Maclure M, Dormuth CR, Glynn RJ. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation. 2007;115(16): 2128-35.
4. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-30.
5. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353(5):487-97.
6. Choudhry NK. Copayment levels and medication adherence: less is more. Circulation. 2009;119(3):365-7.
7. Fendrick AM, Smith DG, Chernew ME, Shah SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care. 2001;7(9):861-7.
8. Choudhry NK, Rosenthal MB, Milstein A. Assessing the evidence for value-based insurance design. Health Aff (Millwood). 2010;20(11): 1988-94.
9. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care. 2005;11(5 Suppl):S170-6.
10. Chernew ME, Shah MR, Wegh A, Rosenberg SN, Juster IA, Rosen AB, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood). 2008;27(1):103-12.
11. Fairman KA, Curtiss FR. Making the world safe for evidence-based policy: let's slay the biases in research on value-based insurance design. J Manag Care Pharm. 2008;14(2): 198-204.
12. To access the Appendix, click on the Appendix link in the box to the right of the article online.
13. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105-16.
14. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002; 27(4):299-309.
15. Kaiser Family Foundation, Health Research and Educational Trust. Employer health benefits: 2007 annual survey [Internet]. Menlo Park (CA): KFF; 2007 Sep [cited 2008 Jan 31]. Available from: http://www.kff.org/insurance/7672/index.cfm
16. Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther. 2003;25(11):2958-2971.
17. Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH. Costeffectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation. 2008;117(10):1261-8.
18. Choudhry NK, Avorn J, Antman EM, Schneeweiss S, Shrank WH. Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. Health Aff (Millwood). 2007;26(1):186-94.
19. Chernew ME, Juster IA, Shah M, Wegh A, Rosenberg S, Rosen AB, et al. Evidence that value-based insurance can be effective. Health Aff (Millwood). 2010;29(3):530-6.
20. Choudhry NK, Brennan T, Toscano M, Spettell C, Glynn RJ, Rubino M, et al. Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies. Am Heart J. 2008;156(1):31-6.
21. Sedjo RL, Cox ER. Lowering copayments: impact of simvastatin patent expiration on patient adherence. Am J Manag Care. 2008;14(12):813-8.
22. Rodin HA, Heaton AH, Wilson AR, Garrett NA, Plocher DW. Plan designs that encourage the use of generic drugs over brand-name drugs: an analysis of a free generic benefit. Am J Manag Care. 2009; 15(12):881-8.
23. Kelly EJ, Turner CD, Frech-Tamas FH, Doyle JJ, Mauceri EG. Valuebased benefit design and healthcare utilization in asthma, hypertension, and diabetes. Am J Pharm Benefits. 2009;1(4):217-21.
24. Chang A, Liberman JN, Coulen C, Berger JE, Brennan TA. Value-based insurance design and antidiabetic medication adherence. Am J Pharm Benefits. 2010;2(1):39-44.
25. Chan DC, Shrank WH, Cutler D, Jan S, Fischer MA, Liu J, et al. Patient, physician, and payment predictors of statin adherence. Med Care. 2010;48(3):196-202.